# Manual Review of Few-Shot Variant Responses

Reviewed 5 representative responses across query categories: HPV biology, single-cell, ML/AI, mutations, and out-of-scope.

## Q01 — HPV prognostic significance in OPSCC

Question: What is the prognostic significance of HPV status in oropharyngeal squamous cell carcinoma?

Response:
Human papillomavirus (HPV) infection is an independent prognostic factor for oropharyngeal squamous cell carcinoma (OPSCC) [PMID:39397259]. HPV-positive OPSCC patients generally exhibit better survival outcomes compared to HPV-negative patients [PMID:39291666, PMID:39397259, PMID:39487900]. Specifically, a significantly lower risk of death has been measured for all HPV-positive tumors compared with HPV-negative tumors, including HPV 16, other high-risk HPV, and low-risk HPV genotypes [PMID:39291666]. HPV-positive patients are also associated with better clinical outcomes, including 5-year overall survival [PMID:34129700].

The prognostic value of HPV genotypes in OPSCC is significant, with superior survival outcomes observed across all HPV genotypes compared to HPV-negative tumors [PMID:39291666]. Immunoglobulin Heavy Constant Mu (IGHM) mRNA is significantly upregulated in HPV-positive OPSCC and is associated with a better prognosis, potentially contributing to these prognostic differences [PMID:39397259].

While p16 immunohistochemistry (IHC) is used as a surrogate marker for HPV status in staging, HPV itself is more prognostic than p16 for OPSCC [PMID:34129700]. The detection of HPV has a significant impact on survival probability for OPSCC patients regardless of p16 status [PMID:39293346]. Patients with p16-positive/HPV-positive OPSCC exhibit the best survival probability [PMID:39293346]. HPV testing, especially HPV RNA ISH, can be adopted for routine analysis and should be integrated into cancer staging alongside p16 evaluation for a comprehensive prognostic assessment [PMID:34129700, PMID:39293346].

- **Cited PMIDs:** ['39397259', '39291666', '39487900', '34129700', '39293346']
- **Verdict:** ✅
- **Notes:** Accurate

## Q06 — Single-cell RNA-seq in HNSCC
Question: What single-cell RNA sequencing studies have characterized HNSCC heterogeneity?

Response:
Single-cell RNA sequencing (scRNA-seq) studies have characterized HNSCC heterogeneity by revealing diverse cellular landscapes and molecular features. Single-cell sequencing analysis of HNSCC tumor tissues identified two clusters of malignant epithelial cells with unique gene expression patterns and dysregulated signaling pathways [PMID:38085162]. Transcriptional heterogeneity was also observed in immune cells within the tumor microenvironment, including macrophages and dendritic cells [PMID:38085162].

In HPV-related oropharyngeal carcinoma, single-cell RNA-seq uncovered a high level of cellular diversity within and between tumors [PMID:37012457]. This diversity includes chromosomal aberrations within individual tumors, heterogeneity in HNSCC subtypes and cellular states like cell cycle, senescence, and epithelial-mesenchymal transitions [PMID:37012457]. Furthermore, heterogeneity in viral gene expression was found within HPV-positive tumors [PMID:37012457].

Single-cell transcriptome analysis also revealed dynamic changes in cell percentage and heterogeneity of cell subtypes in HNSCC, with differing cell composition between sample types [PMID:36157879]. Another study using single-cell RNA-sequencing analysis aimed to determine the heterogeneity of cancer stem cells (CSCs) in HNSCC [PMID:36451812]. This analysis showed that naive CSCs were divided into two different types of cells with distinct functions, exhibiting functional diversity and highlighting the heterogeneity of CSCs [PMID:36451812]. Additionally, single-cell RNA sequencing has been utilized to comprehensively analyze HNSCC at the cellular level, identifying keratinocytes as a predominant cell type in tumor samples [PMID:38421592].

- **Cited PMIDs:** ['38085162', '37012457', '36157879', '36451812', '38421592']
- **Verdict:** ✅ / ⚠️ / ❌
- **Notes:** [your observation]

## Q14 — Machine learning for HNSCC outcome prediction
Question: What machine learning approaches have been applied to HNSCC outcome prediction?

Response:
Various machine learning approaches have been applied to HNSCC outcome prediction. These include tree-based algorithms such as voting ensemble, Light GBM, XGBoost, Random Forest, and Extreme Random Trees for predicting overall survival in oropharyngeal squamous cell carcinoma (OPSCC) [PMID:36279655]. For HNSCC prognosis and drug response, ten algorithms were utilized: CoxBoost, elastic network (Enet), generalized boosted regression modeling (GBM), Lasso, Ridge, partial least squares regression for Cox (plsRcox), random survival forest (RSF), stepwise Cox, supervised principal components (SuperPC), and survival support vector machine (survival-SVM), along with 81 algorithm combinations [PMID:39749326].

Other models used for estimating overall survival in HNSCC patients include TabNet, XGBoost, and voting ensemble [PMID:40121767]. For identifying molecular subtypes and constructing a prognostic model for HNSCC, 10 multi-omics consensus clustering algorithms and 101 algorithms were used, with the Elastic Net model specifically mentioned for selecting prognosis-related genes [PMID:39910672]. The Elastic Net model has also been shown to effectively predict overall survival in recurrent or metastatic HNSCC by bridging surrogate efficacy endpoints and median OS [PMID:40907211].

- **Cited PMIDs:** ['36279655', '39749326', '40121767', '39910672', '40907211']
- **Verdict:** ✅ / ⚠️ / ❌
- **Notes:** [your observation]

## Q15 — TP53 mutations and prognosis
Question: What is the role of TP53 mutations in head and neck cancer prognosis?

Response:
TP53 mutations are an independent prognostic factor in head and neck squamous cell carcinoma (HNSCC) [PMID:37501500]. These mutations are associated with a poor prognosis, shorter progression-free survival, and poor overall survival in HNSCC patients [PMID:40333905, PMID:39727015]. Specifically, cases harboring high-risk-of-death TP53 mutations have an odds ratio of 3.301 for stable or progressive disease compared to wild-type cases [PMID:37501500]. TP53 mutations are linked to aggressive clinical characteristics and poor survival, particularly in HNSCC patients treated with immunotherapy [PMID:39727015].

In HPV-negative hypopharyngeal carcinoma patients, TP53 disruptive mutations are associated with reduced survival, while non-disruptive mutations show a significantly better clinical outcome than disruptive mutations [PMID:37024846]. TP53 mutations can also increase TP53 expression levels and reduce hsa-mir-133b expression, which significantly affects patient survival in HNSCC [PMID:40333905]. Beyond inhibiting tumor suppression, p53 mutations can provide gain-of-function effects that facilitate tumor recurrence [PMID:37449494].

- **Cited PMIDs:** ['37501500', '40333905', '39727015', '37024846', '37449494']
- **Verdict:** ✅ / ⚠️ / ❌
- **Notes:** [your observation]

## Q24 — CAR-T cell therapy for leukemia (out-of-scope)
Question: How does CAR-T cell therapy work for leukemia?

Response:
Information not available in the knowledge base.
- **Cited PMIDs:** []
- **Verdict:** ✅ Refused correctly
- **Notes:** Accurate

## Summary

Of 5 manually reviewed responses:
- **Accurate citations:** [N/5]
- **Refused correctly when expected:** [N/N OOS]
- **Concerns identified:** [list any]

The few-shot variant demonstrated [strong / acceptable / weak] grounding in retrieved evidence. Citation attribution was [accurate / loose / problematic] in qualitative review.